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Abstract
Collagen-induced arthritis (CIA), an approved animal model for
rheumatoid arthritis, is thought to be a T cell-dependent disease.
There is evidence that CD8+  T cells are a major subset
controlling the pathogenesis of CIA. They probably contribute to
certain features of disease, namely tissue destruction and
synovial hyperplasia. In this study we examined the role of
perforin (pfp), a key molecule of the cytotoxic death pathway that
is expressed mainly in CD8+ T cells, for the pathogenesis of CIA.
We generated DBA/1J mice suffering from mutations of the pfp
molecule, DBA/1J-pfp-/-, and studied their susceptibility to
arthritis. As a result, pfp-deficient mice showed a reduced
incidence (DBA/1J-pfp+/+, 64%; DBA/1J-pfp-/-, 54%), a slightly
delayed onset (onset of disease: DBA/1J-pfp+/+, 53 ± 3.6;
DBA/1J-pfp-/-, 59 ± 4.9 (mean ± SEM), and milder form of the
disease (maximum disease score: DBA/1J-pfp+/+, 7.3 ± 1.1;
DBA/1J-pfp-/-, 3.4 ± 1.4 (mean ± SEM); P  < 0.05).
Concomitantly, peripheral T cell proliferation in response to the
specific antigen bovine collagen II was increased in pfp-/- mice
compared with pfp+/+ mice, arguing for an impaired killing of
autoreactive T cells caused by pfp deficiency. Thus, pfp-
mediated cytotoxicity is involved in the initiation of tissue
damage in arthritis, but pfp-independent cytotoxic death
pathways might also contribute to CIA.
Introduction
Collagen-induced arthritis (CIA) is an experimental model of
arthritis inducible in susceptible strains of mice, for example
DBA1/J, by immunization with bovine collagen type II (CII) in
complete Freund's adjuvant (CFA) [1-4]. The development of
CIA is known to depend on T cells, and disease susceptibility
is linked to the major histocompatibility complex (MHC) region
[5]. After T cell activation an inflammatory cascade involving T
cells, macrophages/monocytes, B cells, and activated synovi-
ocytes, is triggered. Different types of leucocytes and synovial
cells produce a complex array of cytokines and other soluble
mediators, which are thought to be responsible for cartilage
destruction and bone erosion [6-9]. Some of the main features
of disease are synovial hyperplasia and mononuclear cell infil-
tration. Factors contributing to this phenomenon are unknown;
however, an imbalance between rates of cell proliferation and
cell death (apoptosis) has been suggested by recent studies
of rheumatoid synovium demonstrating that apoptosis of syn-
ovial cells and infiltrating lymphocytes was common in situ
[10,11]. In the immune system, apoptosis is involved in devel-
opment and in the negative selection of lymphocytes. It is also
crucial in downregulating immune responses to foreign anti-
gens. Cytotoxic T lymphocytes and other killer cells can elimi-
nate their targets by the induction of cell death. All of these
functions are primarily mediated through the receptors Fas/
APO-1, tumor necrosis factor receptor 1 (TNFR1; p55 TNFR)
and the perforin (pfp)/granzyme pathway [12,13].
Perforin is expressed mainly in activated cytotoxic T lym-
phocytes (CTLs) and natural killer (NK) cells, although some
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reports suggest its expression in microglia as well [14]. In
CTLs, pfp is stored in cytoplasmic granules and is a major
effector of cytolysis by these cells. On pfp release it inserts
itself into the plasma membrane of target cells and polymerizes
into pore forming aggregates. Pores of pfp lead to osmotic
lysis of target cells and induce apoptosis by allowing
granzymes to enter the target cells. Perforin-deficient mice
have confirmed its function as an effector molecule and in the
immune response to viruses and tumors as well as in other
aspects of immune regulation such as activation-induced cell
death (AICD), antibody production and spontaneous autoim-
munity [15-17]. NOD mice, an animal model of insulin-depend-
ent diabetes mellitus with a mutation of the pfp gene (NOD/
pfp-mice), develop diabetes with highly reduced incidence
and markedly delayed onset, pointing to a role of the pfp death
pathway in tissue damage in this disease [18].
The role of pfp in arthritis is not clear, although some observa-
tions suggest a role in disease pathogenesis, for example pfp-
expressing CTLs has been demonstrated in the rheumatoid
synovium, and CD8-deficient mice seem to be less suscepti-
ble to induction of collagen-induced arthritis [19].
It is conceivable that the pfp/granzyme pathway could contrib-
ute to the pathology of arthritis in at least two ways: promotion
of autoimmunity by blocking peripheral tolerance and AICD or
destruction of target tissues. In this study we attempted to
evaluate the role of the pfp-mediated death pathway in the
pathogenesis of CIA with the use of pfp-deficient mice (pfp-/-)
by examining the effect of the mutation on the clinical course
of disease, immune response to collagen and on joint
pathology.
Materials and methods
Mice
Perforin-deficient mice were not available on the DBA/1J
background. We obtained pfp-/- C57BL/6J (B6) mice, gener-
ated as described previously [15], from the Jackson Laborato-
ries (Bar Harbor, ME, USA). These mice were backcrossed
onto the CIA-susceptible DBA/1J background (Harlan-Win-
kelmann, Borchen, Germany) for at least 14 generations. The
mice were propagated as hemizygous mutants and the muta-
tions were followed by PCR analysis of tail DNA. To produce
homozygous pfp-/- mice for the experiments, heterozygous pfp-
deficient mice were intercrossed. Successful backcrossing to
the DBA/1J background was assessed by PCR analysis of the
MHC-H2 locus [20]. To select mice heterozygous for the pfp-
deficiency the primers 5'-TTT TTG AGA CCC TGT AGA CCC
A-3' (pfp1) and 5'-GCA TCG CCT TCT ATC GCC TTC T-3'
(pfp2) were used. For selection of homozygous pfp-deficient
mice, pfp3 primer (5'-CCG GTC CTG AAC TCC TGG CCA
A-3') was used in combination with pfp4 primer (5'-CCC CTG
CAC ACA TTA CTG GAA G-3'). Microsatellite markers (Met-
abion GmbH, Planegg-Martinsried, Germany) surrounding the
pfp gene were used for determining the size of the C57BL/6J
DNA fragment in the mutant mice. The amplified microsatel-
lites were separated and analyzed on denaturing polyacryla-
mide gels, and were detected with a LI-COR Model 4200L
automated DNA sequencer (LI-COR Inc., Lincoln, NE, USA).
For the experiments male mice 8 to 16 weeks old were used.
Animals were kept and bred under standard conditions at the
facility of the University of Rostock. All experiments were
approved by the appropriate authorities in the state of Meck-
lenburg-Vorpommern, Germany.
Induction and clinical evaluation of collagen-induced 
arthritis
Age-matched mice were immunized intradermally at the base
of the tail with 125 µg of bovine CII (Chondrex, Redmond, WA,
USA) emulsified in CFA (incomplete Freund's adjuvant con-
taining 4 mg/ml Mycobacterium tuberculosis; Difco Laborato-
ries, Detroit, IL, USA) or with CFA only. Mice were then
boosted with 125 µg of bovine CII in incomplete Freund's
adjuvant at day 21. Blood were taken at day 0 and day 21
before boosting, and serum was collected. Clinical scores
were assessed immediately before immunization (day 0) and
thereafter three times weekly. Inflammation of the four paws
was scored as follows: 0, no inflammation; 1, swelling or red-
ness of one joint; 2, swelling or redness of more than one joint
or mild inflammation of the whole paw; 3, severe inflammation
of whole paw or ankylosis. CFA-immunized mice served as
controls.
T cell proliferation response
Popliteal, preperioteneal, inguinal, mesenterial, axillary and
cervical lymph nodes were removed under aseptic conditions.
Single-cell suspensions of mononuclear cells of pooled lymph
nodes from individual mice were prepared. The cells were cul-
tured in triplicates in flat-bottomed 96-well culture plates, at a
concentration of 2 × 106 cells in 200 µl of medium (RPMI
1640 with Glutamax-II supplemented with 50 IU/ml penicillin,
60 µg/ml streptomycin (Gibco, Karlsruhe, Germany) and 5%
heat-inactivated fetal calf serum). To investigate the antigen-
specific response, lymphocytes were stimulated with 10, 1 or
0.1 µg/ml bovine CII; 4 µg/ml concanavalin A (Difco) was used
as positive control, and medium only was used as negative
control. Cells were incubated for 72 hours at 37°C in a humid-
ified atmosphere containing 5% CO2. To measure the prolifer-
ation by DNA synthesis, cells were pulsed with 1 µCi of
[3H]thymidine for the last 12 hours of culture. Cells were har-
vested onto glass fiber filters, and [3H]thymidine incorporation
was measured in a liquid β -scintillation counter. The results
were expressed as counts per minute.
Cytokine ELISA
To analyze cytokine production, cells were cultured as
described above; supernatant was collected after 72 hours in
vitro antigen challenge. Concentrations of IFN-γ  in the super-
natants were determined by the Cytoscreen Immunoassay Kit
(BioSource, Camarillo, CA, USA) in accordance with theAvailable online http://arthritis-research.com/content/7/4/R877
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instructions of the manufacturer. In brief, the lymphocyte
supernatant was added to an ELISA-plate coated with a mon-
oclonal antibody specific for mouse IFN-γ . After incubation and
washing, a biotinylated polyclonal antibody specific for mouse
IFN-γ  was added. Then streptavidin–peroxidase and later the
substrate solution were added to detect the products of the
reaction.
Anti-CII antibody assay
The serum from the mice was analyzed with ELISA for the
quantification of IgG antibodies against CII. Micro-ELISA
plates were coated overnight at 4°C with 50 µl of PBS con-
taining 5 µg/ml bovine CII in each well. After washing, the sera
were added and incubated at 37°C for 2 hours. After 1 hour
of incubation at 37°C with anti-mouse-IgG conjugated with
alkaline phosphatase (Pharmingen BD), p-nitrophenylphos-
phate containing substrate buffer (Sigma) was added, and 3
M NaOH was used to stop the reaction. The plates were read
at 405 nm.
Histopathology
Mice were killed and paws were cut off and subsequently fixed
in 4% paraformaldehyde solution. After decalcification for 2 to
3 weeks in an EDTA solution the paws were embedded in par-
affin. The paws were sectioned and stained with H & E. Evalu-
ation of disease was made according to a previously published
scale [21]: 1, synovial hyperplasia; 2, start of pannus develop-
ment; 3, erosions of bone and cartilage; 4, severe inflammation
and erosions.
Fluorescence-activated cell sorting analysis
For the determination of T cell, B cell and NK cell populations
in the different pfp-mice, lymphocytes were isolated and
stained with fluorescein isothiocyanate (FITC)-labeled anti-
CD4 antibody (Pharmingen; clone H129.19), phycoerythrin-
labeled anti-CD8a antibody (Pharmingen; clone 43-6.7), FITC-
labeled anti-CD45R/B220 antibody (Pharmingen; clone RA3-
6B2), phycoerythrin-labeled anti-CD90 antibody (Pharmingen;
clone OX-7), and anti-IgG-biotin and streptavidin-FITC before
being analyzed by FACScan (Becton Dickinson; with Cell
Quest software version 1.2.2).
Statistics
Statistical evaluation was performed with SPSS software. For
analyzing differences in clinical scores, a Mann–Whitney test
was used. For incidence calculations, χ 2 and Fisher tests were
used. When analyzing differences in cytokine production and
T cell proliferation, Student's unpaired t-test was used. Differ-
ences were considered significant at P < 0.05.
Results
Characterization of the pfp-deficient DBA/1J mice
The pfp-deficient mice were originally derived from C57BL/6J
strain by embryonic stem cell transfer. Because this strain is
resistant to CIA induction, we backcrossed the mice for at
least 14 generations into the CIA-susceptible DBA/1J back-
ground. The pfp gene is located on chromosome 10 at 36 cM,
and the mutant gene was inherited as a C57BL/6J fragment of
about 10 cM between about 28 and 39 cM (Table 1). To
exclude the possibility that backcrossing with the DBA/1J
strain revealed a defect in T cell, B cell or NK cell maturation
we examined distribution of these different immune cell popu-
Table 1
Mapping of DBA perforin-deficient mice
Marker Position (cM) Parental
D10Mit38 26.8 DBA
D10Mit44 27 DBA
D10Mit194 29 C57BL/6J
D10Mit61 32 C57BL/6J
D10Mit20 35 C57BL/6J
D10Mit31 36 C57BL/6J
D10Mit32 38 C57BL/6J
D10Mit186 40 DBA
D10Mit174 41 DBA
D10Mit175 41.8 DBA
D10Mit42 44 DBA
D10Mit261 47 DBA
D10Mit67 49 DBA
The mice were backcrossed for 14 generations to the DBA/1J background.Arthritis Research & Therapy    Vol 7 No 4    Bauer et al.
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lations by fluorescence-activated cell sorting. It was found that
T lymphocytes expressing CD4 and CD8, as well as CD90+
cells (CD90 is expressed on T cells and NK cells) and
CD45R/B220-positive cells (B cells, activated killer cells)
were present at comparable percentages in heterozygous and
pfp-deficient DBA/1J mice, indicating that the lack of pfp did
not affect development of these cell populations in the DBA/
1J strain (data not shown). The lack of pfp expression in the
activated T cells of the pfp-/- mice was confirmed at the RNA
level by RT-PCR (see Additional file 1a).
Pfp-deficient mice are less susceptible to collagen-
induced arthritis
To investigate the role of pfp in collagen-induced arthritis, we
immunized DBA-pfp-/-, DBA-pfp+/- and DBA-pfp+/+ mice with
bovine CII in CFA. As shown in Fig. 1 and Table 2, mice defi-
cient for pfp developed a less severe disease with lower clini-
cal scores than mice with intact pfp. DBA-pfp-/- mice also
showed a tendency to a delayed onset of CIA. Mice with intact
pfp (pfp+/+ and pfp+/-) had an average incidence of 64%,
whereas pfp-/- mice showed a mean incidence of 54% (Fig. 1).
The severity of disease was decreased on day 50 after immu-
nization (pfp-/-, 0.9 ± 0.86; pfp+/-, 1.4 ± 0.67; pfp+/+, 1.3 ±
0.47 (means ± SEM)), and on day 75 (pfp-/-, 2.1 ± 1.7; pfp+/-,
3.8 ± 1; pfp+/+, 5.2 ± 1.2), and significantly decreased on day
82 (pfp-/-, 3.0 ± 1.5; pfp+/-, 4.0 ± 0.9; pfp+/+, 5.6 ± 0.9; P <
0.05). Maxscore, calculated as the mean of the maximum
score value for each individual mouse of a given genotype,
was also significantly decreased in pfp-deficient mice (pfp-/-
3.4 ± 1.45) in comparison with pfp+/+ mice (7.3 ± 1.14; Fig.
1). In addition, the area under the curve, as a measure of sever-
ity, onset and chronicity, was significantly lower in pfp-/- mice
than in mice carrying pfp (pfp-/-, 31.9 ± 23; pfp+/-, 44.6 ±
12.3).
Histopathological features of CIA do not change with pfp 
deficiency
To investigate joint histopathology, paws were dissected from
pfp-/- and pfp+/- mice with CIA, H & E-stained and evaluated
blind for signs of arthritis. Results (Fig. 2) reveal that pfp-/- mice
Table 2
Summary of disease-related data of perforin-deficient (pfp-/-) mice compared with pfp+/- and pfp+/+ mice
Genotype (n) Day of onset Incidence (%) Severity Maxscore AUC
Day 50 Day 75 Day 82
Pfp-/- (13) 59 ± 4.9 54 0.9 ± 0.8 2.1 ± 1.6 3.0 ± 1.5a 3.4 ± 1.4b 31.9 ± 23.0c
Pfp+/- (14) 52 ± 3.5 64 1.4 ± 0.6 3.8 ± 0.9 4.0 ± 0.9a 5.6 ± 1.2b 44.6 ± 12.3c
Pfp+/+ (14) 53 ± 3.6 64 1.3 ± 0.4 5.2 ± 1.2 5.6 ± 0.9a 7.3 ± 1.1b 59.4 ± 16.7
Evaluations and analyses were performed as described in Materials and methods. Maxscore was calculated as the mean of the maximum score 
value for each individual mouse of a given genotype. Data are group mean values ± SEM. Values with the same superscript letter are significantly 
different (P < 0.05). AUC, area under the curve.
Figure 1
Perforin-deficient (pfp-/-) mice develop decreased collagen-induced  arthritis (CIA) Perforin-deficient (pfp-/-) mice develop decreased collagen-induced 
arthritis (CIA). Percentage of CIA-affected animals (a) is decreased and 
average maximum score (b) is significantly lower in pfp-/- mice than in 
pfp+/- and pfp+/+ mice. Figures show results from two different experi-
ments, with balanced groups, taken together. Maxscore was calculated 
as the mean maximum score for each individual mouse of a given geno-
type. *P < 0.05.Available online http://arthritis-research.com/content/7/4/R877
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can develop a severe arthritis with typical signs of CIA, namely
proliferation of synoviocytes, infiltration of inflammatory cells,
pannus development, and erosions of bone and cartilage.
Comparing both genotypes, no differences in histopathologi-
cal development of the disease were visible (Fig. 2).
Lack of pfp does not affect the antibody response to 
collagen
To investigate the role of pfp on the humoral immune response
to collagen, sera were obtained from pfp-/-, pfp+/- and pfp+/+
mice at days 0 and 21 after immunization, and the levels of CII-
specific IgG antibodies were measured by quantitative ELISA.
No significant variations were seen in the levels of anti-CII-spe-
cific IgG between the pfp-/- and pfp+/- or pfp+/+ littermates (Fig.
3). Pfp-deficient mice showed a mean titer of anti-CII antibod-
ies of 233 ± 51.1, and the control group had a mean titer of
anti-CII antibodies of 306 ± 50.8 at day 21 after immunization.
These data show that even without pfp the mice develop a
strong humoral immune response against CII, suggesting that
the lack of pfp does not affect the anti-CII antibody response.
Pfp-/- mice mount an enhanced proliferative T cell 
response toward CII
To investigate whether the T cell response against CII was
affected by pfp deficiency, draining the lymph nodes of immu-
nized pfp-/- and pfp+/+ was investigated for the proliferative
response toward bovine CII. Perforin-deficient mice showed
an enhanced T cell proliferation compared with pfp wild-type
mice. As shown in Fig. 3, after stimulation with 0.1 µg/ml CII,
pfp-/- mice showed a significantly elevated T cell proliferation
of 12,835 ± 2,750 cpm compared with 4,727 ± 1,268 cpm in
pfp+/+ mice; at a CII concentration of 1 µg/ml the T cell prolif-
eration was also significantly increased in pfp-deficient mice
(32,209 ± 6,764 cpm) compared with pfp-wild-type mice
(21,904 ± 2,626 cpm). The IFN-γ  production of T cells from
these mice was measured by ELISA, but no significant differ-
ences between pfp-/- and pfp+/+ mice were observed (data not
shown).
Discussion
The primary aim of this study was to investigate whether the
delayed onset and mild arthritis observed earlier in CD8-/- mice
[19] is due to a lack of cytotoxic ability or a lack of some other
aspects of T cell function such as the secretion of cytokines.
Indeed, we found that pfp-deficient mice develop disease with
reduced incidence, a slightly delayed onset, and significantly
decreased severity, suggesting that CTL activity is important
for the initiation and maintenance of arthritis in the CIA model.
This is in agreement with earlier observations in the insulin-
dependent diabetes mellitus (NOD) mouse model. In that
model, as in CIA, pfp is a susceptible rather than a protective
gene. This is in contrast to other disease models, for example
Figure 2
Histopathology of perforin-deficient pfp-/- mice compared with pfp+/- mice Histopathology of perforin-deficient pfp-/- mice compared with pfp+/- mice. (a) Joint of a pfp-/- mouse with severe inflammation and erosions, stage 4. 
(b) Paw of a heterozygous mouse in the same stage of disease. (c) Comparison of histological and clinical evaluation of the disease. Data are values 
of severity of pfp+/- mice (n = 6) and pfp-/- mice (n = 6), and are shown as means ± SEM.Arthritis Research & Therapy    Vol 7 No 4    Bauer et al.
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experimental autoimmune encephalomyelitis (EAE), systemic
lupus erythematosus (SLE) and autoimmune pancreatitis, in
which pfp clearly protects against the disease [16-18,22]. The
protective effects of pfp could be explained by its immune
regulatory function, namely the killing of autoreactive B cells
and functional self-lysis of activated T cells through AICD.
Hence, its role in regulation of peripheral tolerance and its role
in autoimmunity, which is distinct from, but overlaps, the role of
the FasL/Fas and TNF/TNFR pathways, might be the reason
for accelerated autoimmunity in pfp-deficient mice in the EAE
and SLE models.
In the present study we obtained evidence that pfp can also
act as a susceptibility gene rather than a protective gene. A
lack of the molecule led to reduced severity throughout the
disease, a slightly delayed onset, and a reduced incidence of
CIA. However, we also observed a strong anti-collagen B cell
response with similar anti-collagen-specific IgG levels in con-
trol and pfp-/- mice, and significantly increased T cell prolifera-
tion in response to collagen. This might have been due to a
reduced killing and accumulation of autoreactive T cells after
activation because of impaired AICD. These findings indicate
that a diminished adaptive response to collagen was not
responsible for the reduced arthritis.
Previous studies demonstrated a strong involvement of pfp in
the control of CD8+ T cell homeostasis. Perforin deficiency
resulted in enhanced CD8+  T cell expansion because of
decreased killing of antigen-presenting cells and consequen-
tial prolonged stimulation by antigen [23,24]. Our results
support these propositions: we observed a significantly
increased T cell proliferation in pfp-deficient mice in compari-
son with controls. These data also suggest a role of pfp in the
regulation of T cell homeostasis. Nevertheless, cytokines pro-
duced by cytotoxic T cells are also involved in the regulation of
the T cell response. TNF-α , for example, can mediate AICD of
CD8+ T cells through TNFR1 and TNFR2 [25].
The histopathology of CIA in wild-type pfp+/+ mice of the
present study was similar to that seen in previous studies [26].
Figure 3
Antibody response and T cell proliferation Antibody response and T cell proliferation. (a) No significant variations in the levels of collagen-specific IgG antibodies between the perforin (pfp)-
deficient mice (n = 6) and the control littermates (pfp+/- and pfp+/+; n = 10) were seen. Sera were obtained from the mice 21 days after immunization 
with collagen type II (CII) and complete Freund's adjuvant (CFA). Levels of collagen-specific IgG antibodies were measured by quantitative ELISA. 
(b) pfp-/- mice show an increased proliferation toward CII. Draining lymph nodes were obtained from pfp-/- (n = 3) and pfp+/+ (n = 3) mice 90 days 
after immunization with CII in CFA. The cells were cultured for 60 hours with collagen II in different concentrations, and then pulsed with [3H]thymi-
dine. *P < 0.05.Available online http://arthritis-research.com/content/7/4/R877
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The data are therefore not shown again here. In the present
study there were no significant differences between his-
topathological changes of pfp+/- and pfp-/- mice, most probably
because of a severe disease in individual pfp-/- mice. This
result argues for an additional involvement of pfp-independent
death pathways in joint destruction. Indeed, pfp was upregu-
lated in the inflamed arthritic joints of wild-type mice as shown
by RT-PCR (Additional file 1b).
This is similar to our recent finding showing that the FasL/Fas
pathway has a proinflammatory role in CIA and an activating
function on fibroblasts in vitro [27]. Fas-deficient mice devel-
oped arthritis that was less severe, probably through a
reduced IL-1R1/Toll-like receptor-4 signaling that might con-
tribute to a decreased expression of other cytokines, chemok-
ines and matrix metalloproteinases potentially regulated by this
pathway [28]. Previous studies also reported a strong involve-
ment of the TNF/TNFR pathway because CIA only developed
with a reduced disease incidence, and the severity and neu-
tralization of TNF led to the prevention of arthritis [29,30].
Taken together, the results show that in CIA the disease-pro-
moting effect of pfp prevails. It is therefore tempting to specu-
late that pfp could contribute to arthritis in at least two ways.
First, it could promote tissue damage by direct cytotoxic
effects through CD8+ T cells and NK cells. Second, pfp might
have some activating functions on fibroblasts or macrophages,
leading to the production of proinflammatory cytokines.
Indeed, there are reports indicating that fibroblasts and mono-
cytes can be activated by granzyme A to secrete the proinflam-
matory cytokines IL-6, IL-8 and TNF-α , which could
subsequently severely regulate the inflammatory response
[31,32].
There are other indications that argue for a prominent role of
pfp in arthritis. Perforin was found to be differentially
expressed in lymph nodes and joints of DBA/1J and FVB/N
(CIA-resistant strain) mice (SM Ibrahim and D Koczan, unpub-
lished observations) and pfp-expressing cytotoxic T lym-
phocytes and increased apoptosis were observed in the
synovia of patients with rheumatoid arthritis [10,33,34]. The
targeted pfp gene is likely to have a major role in the observed
effects, on the basis of the absence of pfp production,
although it is possible that other polymorphic genes in the
linked region could also contribute to CIA reduction. Indeed,
the pfp gene is mapped to a CIA-susceptible locus, Cia8 on
chromosome 10. This quantitative trait locus is covered by the
12 cM C57BL/6J fragment including the mutant pfp gene. The
Cia8 region contains several candidate genes that have been
implicated in the modulation of CIA susceptibility, for example
the macrophage migration inhibitory factor Mif [35] and the
autoimmune regulator Aire [36]. However, the observation that
heterozygous littermates and pfp+/+  mice that were also
backcrossed and contained the same or smaller C57BL/6J
fragments do not show effects on the disease argues against
a major role for another gene.
In summary, the CIA in pfp-deficient mice was mild and
showed delayed onset and reduced incidence, but some indi-
vidual pfp-/- mice also developed a severe disease. These
results suggest that pfp-dependent cytotoxicity is involved in
the initiation of tissue damage in arthritis, but that pfp-inde-
pendent cytotoxic death pathways, for example the FasL/Fas
pathway, might also contribute to CIA.
Conclusion
We report that arthritis developed only with reduced inci-
dence, severity and delayed onset in pfp-deficient DBA/1J
mice. These findings suggest that pfp-dependent cytotoxicity
is involved in the initiation of tissue damage in arthritis but also
that one or several other pfp-independent mechanisms, possi-
bly involving FasL/Fas, contribute to the early phase of joint
destruction in CIA.
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